Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics

QR Code

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics

Larry Alphs,1 Cynthia A Bossie,1 Jennifer Kern Sliwa,2 Dong-Jing Fu,1 Yi-Wen Ma,3 Joseph Hulihan11CNS Medical Affairs, 2Medical Information, Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 3Biostatistics, B&amp;P, Janssen Research &amp; Development LLC, Titusville, NJ, USABackg...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Alphs L, Bossie CA, Sliwa JK, Fu DJ, Ma YW, Hulihan J
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2013
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/d4e09e5894fa4a95aa787599beec5147
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
par: Sliwa JK, et autres
Publié: (2012)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
par: Louz&atilde; M, et autres
Publié: (2011)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
par: Hong Liu-Seifert, et autres
Publié: (2009)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
par: Dhiren Singh, et autres
Publié: (2009)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
par: Zhao Y, et autres
Publié: (2013)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
par: Samtani MN, et autres
Publié: (2013)

Clinical utility of the risperidone formulations in the management of schizophrenia
par: Madaan V, et autres
Publié: (2011)

Risperidone long-acting injection: a review of its long term safety and efficacy
par: Michael K Rainer
Publié: (2008)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
par: Takahashi M, et autres
Publié: (2012)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
par: Such P, et autres
Publié: (2021)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
par: Li N, et autres
Publié: (2018)

Emerging treatments in the management of bipolar disorder &ndash; focus on risperidone long acting injection
par: Wissam El-Hage, et autres
Publié: (2010)

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
par: Mario Louz&atilde;, et autres
Publié: (2010)

Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
par: Jeffrey R Bishop, et autres
Publié: (2008)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Risperidone improves interpersonal perception and executive function in patients with schizophrenia
par: Zhou Z, et autres
Publié: (2016)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
par: Gopal S, et autres
Publié: (2013)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
par: Srihari Gopal, et autres
Publié: (2017)

Risperidone-induced reversible neutropenia
par: Kattalai Kailasam V, et autres
Publié: (2017)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
par: Mathews M, et autres
Publié: (2019)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
par: Zhang F, et autres
Publié: (2015)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
par: Adel Gabriel
Publié: (2010)

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
par: Hongyan Zhang, et autres
Publié: (2011)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
par: Suda A, et autres
Publié: (2018)

Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
par: Michele Fabrazzo, et autres
Publié: (2021)

Once-monthly paliperidone injection for the treatment of schizophrenia
par: Delia Bishara
Publié: (2010)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
par: Gopal S, et autres
Publié: (2020)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
par: Gao K, et autres
Publié: (2013)

Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
par: Ranjbar F, et autres
Publié: (2015)

Risperidone treatment for ADHD in children and adolescents with bipolar disorder
par: Joseph Biederman, et autres
Publié: (2008)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
par: Lopez A, et autres
Publié: (2019)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
par: Sugawara N, et autres
Publié: (2019)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
par: Nash AI, et autres
Publié: (2019)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
par: Srihari Gopal, et autres
Publié: (2011)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
par: Pietrini F, et autres
Publié: (2019)

Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents
par: Roberto Canitano, et autres
Publié: (2008)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
par: Gattaz WF, et autres
Publié: (2020)